ABITUZUMAB Anti-Integrin alpha(nu) (CD51, ITGAV) MAb, Oncolytic

摘要

Colorectal cancer is the third most commonly diagnosed cancer in men, and the second in women, while prostate cancer is the second most commonly diagnosed cancer in men. The alpha-nu (alpha(nu)) integrins are a subfamily of integrins that are highly expressed on tumor cells and the tumor vasculature of highly metastatic human cancers. Abituzumab (EMD-525797, DI17E6) is a new, humanized IgG(2) monoclonal antibody specifically directed against the alpha(nu) subunit of human integrin receptors, which is currently in phase II clinical trials for the treatment of metastatic colorectal and metastatic castration-resistant prostate cancers. In a phase II clinical trial in metastatic colorectal cancer patients (POSEIDON), abituzumab showed a trend towards a longer progression-free survival, overall survival and a better response rate in patients harboring tumors with a high integrin alpha(nu)beta(6) expression. Meanwhile, in metastatic castration-resistant prostate cancer patients (PERSEUS), abituzumab elicited a modest improvement in progression-free survival, and in the incidence of bone lesions.